Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 9 |
| List of Tables | 5 | 2 |
| List of Figures | 7 | 5 |
| Clinical Trial Design in Central Nervous System - Overview | 12 | 2 |
| Introduction | 12 | 1 |
| Types of Clinical Trial Outcomes | 12 | 1 |
| Primary Outcomes | 12 | 1 |
| Secondary Outcomes | 12 | 1 |
| GBI Research Report Guidance | 13 | 1 |
| Endpoints - Clinical Trials in CNS Disorders - Top Five CNS Disorders and their Product Profiling | 14 | 4 |
| Endpoints-Major Marketed Drugs of Top Five Central Nervous System Disorders and their Regulatory Approval | 14 | 1 |
| Alzheimer s disease | 15 | 1 |
| Depression | 15 | 1 |
| Epilepsy | 16 | 1 |
| Parkinson s disease | 16 | 1 |
| Schizophrenia | 17 | 1 |
| Endpoints - Clinical Trials in CNS Disorders Marketed and Pipeline Product Assessments | 18 | 183 |
| Alzheimer s disease | 18 | 1 |
| Primary Endpoints used in Alzheimer s disease Clinical Trials | 19 | 1 |
| Secondary Endpoints used in Alzheimer s disease Clinical Trials | 19 | 1 |
| Major Marketed Drugs-Safety and Efficacy Analysis | 19 | 1 |
| Aricept (donepezil hydrochloride) | 19 | 2 |
| Exelon (rivastigmine titrate) | 21 | 1 |
| Namenda (memantine hydrochloride) | 22 | 1 |
| Cognex | 23 | 1 |
| Razadyne (galantamine hydrobromide extended release capsules) | 24 | 1 |
| Phase III Clinical Trial Analysis | 25 | 1 |
| Primary Endpoints of Phase III Completed Trials | 25 | 3 |
| Secondary Endpoints of Phase III Completed Trials | 28 | 7 |
| Primary Endpoints of Phase III Ongoing Trials | 35 | 2 |
| Secondary Endpoints of Phase III Ongoing Trials | 37 | 4 |
| Most Promising Drugs Profiles | 41 | 1 |
| Bapineuzumab | 41 | 1 |
| Gammagard | 42 | 1 |
| Dimebon | 43 | 1 |
| Rember (Trx0014) (methylthionium chloride) | 43 | 2 |
| Phase II Clinical Trial Analysis | 45 | 1 |
| Primary Endpoints of Phase II Completed Trials | 45 | 3 |
| Secondary Endpoints of Phase II Completed Trials | 48 | 7 |
| Primary Endpoints of Phase II Ongoing Trials | 55 | 2 |
| Secondary Endpoints of Phase II Ongoing Trials | 57 | 4 |
| Terminated Trials Analysis | 61 | 1 |
| Depression | 62 | 1 |
| Primary Endpoints used in Clinical Trials for Depression | 63 | 1 |
| Secondary Endpoints used in Clinical Trials for Depression | 63 | 1 |
| Major Marketed Drugs-Safety and Efficacy Analysis | 64 | 1 |
| Lexapro/Cipralex (Escitalopram oxalate) | 64 | 1 |
| Cymbalta (Duloxetine Hydrochloride) | 65 | 1 |
| Abilify (Aripiprazole) | 66 | 1 |
| Pristiq (Desvenlafaxine succinate) | 67 | 1 |
| Symbyax (Olanzapine and fluoxetine Hcl) | 68 | 1 |
| Viibryd (Vilazodone Hydrochloride) | 69 | 1 |
| Phase III Clinical Trial Analysis | 70 | 1 |
| Primary Endpoints of Phase III Completed Trials | 70 | 3 |
| Secondary Endpoints of Phase III Completed Trials | 73 | 6 |
| Primary Endpoints of Phase III Ongoing Trials | 79 | 1 |
| Secondary Endpoints of Phase III Ongoing Trials | 79 | 1 |
| Most Promising Drugs Profiles | 79 | 1 |
| TC 5214 | 79 | 1 |
| LU AA21004 | 80 | 1 |
| Phase II Clinical Trial Analysis | 81 | 1 |
| Primary Endpoints of Phase II Completed Trials | 81 | 3 |
| Secondary Endpoints of Phase II Completed Trials | 84 | 3 |
| Primary Endpoints of Phase II Ongoing Trials | 87 | 1 |
| Secondary Endpoints of Phase II Ongoing Trials | 87 | 1 |
| Terminated Trials Analysis | 87 | 1 |
| Epilepsy | 88 | 1 |
| Primary Endpoints used in Clinical Trials for Epilepsy | 89 | 1 |
| Secondary Endpoints used in Clinical Trials for Epilepsy | 90 | 1 |
| Major Marketed Drugs-Safety and Efficacy Analysis | 90 | 1 |
| Drug Name Lyrica (Pregabalin) | 90 | 2 |
| Gabitril (Tiagabine Hcl) | 92 | 1 |
| Banzel (Rufinamide) | 93 | 1 |
| Vimpat (Lacosamide) | 94 | 1 |
| Sabril (Vigabatrin) | 95 | 1 |
| Phase III Clinical Trial Analysis | 96 | 1 |
| Primary Endpoints of Phase III Completed Trials | 96 | 2 |
| Secondary Endpoints of Phase III Completed Trials | 98 | 7 |
| Primary Endpoints of Phase III Ongoing Trials | 105 | 1 |
| Secondary Endpoints of Phase III Ongoing Trials | 106 | 2 |
| Most Promising Drugs Profiles | 108 | 1 |
| Stedesa (Eslicarbazepine Acetate) | 108 | 1 |
| Comfyde (Carisbamate) | 109 | 1 |
| Retigabine | 110 | 1 |
| Brivaracetam | 111 | 1 |
| Ganaxolone | 112 | 1 |
| E2007 (Perampanel) | 113 | 1 |
| Phase II Clinical Trial Analysis | 114 | 1 |
| Primary Endpoints of Phase II Completed Trials | 114 | 2 |
| Secondary Endpoints of Phase II Completed Trials | 116 | 5 |
| Primary Endpoints of Phase II Ongoing Trials | 121 | 1 |
| Secondary Endpoints of Phase II Ongoing Trials | 121 | 1 |
| Terminated Trials Analysis | 122 | 1 |
| Parkinson s disease | 123 | 1 |
| Primary Endpoints used in Clinical Trials for Parkinson s disease | 123 | 1 |
| Secondary Endpoints used in Clinical Trials Parkinson s disease | 124 | 1 |
| Major Marketed Drugs-Safety and Efficacy Analysis | 124 | 1 |
| Stalevo (levodopa, carbidopa, entacapone) | 124 | 1 |
| Requip XL (ropinirole XL) | 125 | 1 |
| Azilect (rasagiline mesylate) | 126 | 1 |
| Mirapex/Sifrol/Mirapexin (pramipexole dihydrochloride) | 127 | 1 |
| Comtan (entacapone) | 128 | 1 |
| Tasmar (tolcapone) | 129 | 1 |
| Phase III Clinical Trial Analysis | 130 | 1 |
| Primary Endpoints of Phase III Completed Trials | 130 | 3 |
| Secondary Endpoints of Phase III Completed Trials | 133 | 7 |
| Primary Endpoints of Phase III Ongoing Trials | 140 | 1 |
| Secondary Endpoints of Phase III Ongoing Trials | 141 | 3 |
| Most Promising Drugs Profiles | 144 | 1 |
| Safinamide | 144 | 1 |
| Pimavanserin (ACP-103) | 145 | 1 |
| PD-02 | 146 | 1 |
| SLV 308 (pardoprunox) | 147 | 1 |
| Lisuride (patch and subcutaneous (sc) infusion) | 147 | 1 |
| IPX066 | 148 | 1 |
| Phase II Clinical Trial Analysis | 149 | 1 |
| Primary Endpoints of Phase II Completed Trials | 149 | 3 |
| Secondary Endpoints of Phase II Completed Trials | 152 | 6 |
| Primary Endpoints of Phase II Ongoing Trials | 158 | 2 |
| Secondary Endpoints of Phase II Ongoing Trials | 160 | 2 |
| Terminated Trials Analysis | 162 | 1 |
| Schizophrenia | 163 | 1 |
| Primary Endpoints used in Clinical Trials for Schizophrenia | 164 | 1 |
| Secondary Endpoints used in Clinical Trials for Schizophrenia | 164 | 1 |
| Major Marketed Drugs-Safety and Efficacy Analysis | 165 | 1 |
| Zyprexa (olanzapine) | 165 | 1 |
| Abilify (aripiprazole) | 165 | 1 |
| Seroquel/Seroquel XR (quetiapine) | 166 | 1 |
| Geodon (ziprasidone) | 167 | 1 |
| Invega (paliperidone) | 168 | 1 |
| Fanapt (iloperidone) | 168 | 1 |
| Saphris (asenapine) | 169 | 1 |
| Serdolect (sertindole) | 170 | 1 |
| Phase III Clinical Trial Analysis | 171 | 1 |
| Primary Endpoints of Phase III Completed Trials | 171 | 4 |
| Secondary Endpoints of Phase III Completed Trials | 175 | 10 |
| Primary Endpoints of Phase III Ongoing Trials | 185 | 1 |
| Secondary Endpoints of Phase III Ongoing Trials | 186 | 2 |
| Most Promising Drugs Profiles | 188 | 1 |
| Lurasidone | 188 | 1 |
| Cariprazine (RGH-188) | 188 | 1 |
| LY2140023 | 189 | 1 |
| Staccato Loxapine, AZ-004 | 190 | 1 |
| Phase II Clinical Trial Analysis | 191 | 1 |
| Primary Endpoints of Phase II Completed Trials | 191 | 3 |
| Secondary Endpoints of Phase II Completed Trials | 194 | 4 |
| Primary Endpoints of Phase II Ongoing Trials | 198 | 1 |
| Secondary Endpoints of Phase II Ongoing Trials | 199 | 1 |
| Terminated Trials Analysis | 200 | 1 |
| Endpoints - Clinical Trials in CNS Disorders - Company Profiles | 201 | 12 |
| Pfizer Inc. | 201 | 1 |
| Company Profile | 201 | 1 |
| Major Central Nervous System Disorders Products | 201 | 1 |
| GlaxoSmithKline Plc | 202 | 1 |
| Company Profile | 202 | 1 |
| Major Central Nervous System Disorders Products | 202 | 1 |
| AstraZeneca Plc | 203 | 1 |
| Company Profile | 203 | 1 |
| Major Central Nervous System Disorders Products | 203 | 1 |
| Sanofi | 204 | 1 |
| Company Profile | 204 | 1 |
| Major Central Nervous System Disorders Products | 204 | 1 |
| Johnson &Johnson | 205 | 1 |
| Company Profile | 205 | 1 |
| Major Central Nervous System Disorders Products | 205 | 2 |
| Eli Lilly and Company | 207 | 1 |
| Company Profile | 207 | 1 |
| Major Central Nervous System Disorders Products | 207 | 1 |
| Novartis AG | 208 | 1 |
| Company Profile | 208 | 1 |
| Major Central Nervous System Disorders Products | 208 | 2 |
| Abbott Laboratories | 210 | 1 |
| Company Profile | 210 | 1 |
| Major Central Nervous System Disorders Products | 210 | 1 |
| Forest Laboratories, Inc | 211 | 1 |
| Company Profile | 211 | 1 |
| Major Central Nervous System Disorders Products | 211 | 1 |
| Eisai Co., Ltd | 212 | 1 |
| Company Profile | 212 | 1 |
| Major Central Nervous System Disorders Products | 212 | 1 |
| Endpoints - Clinical Trials in CNS Disorders - Appendix | 213 | 4 |
| Market Definitions | 213 | 1 |
| Abbreviations | 213 | 1 |
| Research Methodology | 214 | 2 |
| Clinical Trial Design Overview | 215 | 1 |
| Marketed and Pipeline Products Assessment | 215 | 1 |
| Company Profiles | 215 | 1 |
| Contact Us | 216 | 1 |
| Disclaimer | 216 | 1 |
| Sources | 216 | 1 |